Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Mesothelioma • NCI-CCC Thoracic Tumor Board Question
How are you choosing between ipilimumab/nivolumab versus platinum/pemetrexed for unresectable epithelioid mesotheliomas?
Answer from: Medical Oncologist at Academic Institution
Although the combination of ipi/nivo has been approved for all unresectable mesotheliomas, the benefit was much more impressive in the NON-epithelioid histologies. Therefore, for patients with epithelioid mesothelioma, I follow the NCCN recommendations where I would discuss both platinum/pemetrexed ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
The CheckMate 743 study [Baas et al., PMID 33485464] is an important trial for malignant mesothelioma that randomized 605 patients to first line ipilimumab + nivolumab versus platinum-pemetrexed chemotherapy. Based on a pre-specified interim analysis, ipilimumab + nivolumab extended overall survival...